<DOC>
	<DOCNO>NCT01236352</DOCNO>
	<brief_summary>The purpose first human study determine BMS-911543 safe tolerable subject symptomatic intermediate-1 , intermediate-2 high risk myelofibrosis permit clinical test Maximum Tolerated Dose Clinically Active Dose , determine BMS-911543 demonstrate efficacy symptomatic myelofibrosis .</brief_summary>
	<brief_title>Multiple Ascending Dose BMS-911543</brief_title>
	<detailed_description>Endpoint Classification : Phase 1 : Dose Ranging/Safety Phase 2 : Safety/Efficacy</detailed_description>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Men Women least 18 year old A diagnosis symptomatic , primary secondary Myelofibrosis ( MF ) [ World Health Organization ( WHO ) 2008 criterion ] intermediate1 , intermediate2 high risk disease assess use Dynamic International Prognostic Scoring System international prognostic scoring system Last therapeutic diagnostic treatment least 28 day prior Any toxicity prior therapy must resolve Grade ≤1 Adequate Liver Kidney Function Serum amylase lipase within normal institutional range Platelet count ≥50,000 cell mm³ Absolute neutrophil count ( ANC ) ≥1,000 cells/mm3 Hemoglobin ≥8.0 g/dL Primary central nervous system tumor Subjects currently active malignancy ( MF ) prior history malignancy exception : ( ) adequately treat basal cell carcinoma skin , ( ii ) curatively treat situ carcinoma cervix , ( iii ) malignancy undergone potentially curative therapy evidence disease recurrence ≥3 year Any condition require chronic use moderate/high dose steroid except inhalation oral steroid mild pulmonary disease Splenic irradiation ≤3 month prior treatment study drug Positive blood screen hepatitis C antibody , hepatitis B surface antigen Human Immunodeficiency Virus1 ( HIV1 ) , HIV2 antibodies Abnormalities serum electrolytes Significant cardiovascular disease Current recent gastrointestinal disease Previous history pancreatitis and/or significant risk factor pancreatitis judge treat physician Evidence uncontrolled active infection active graft vs. host disease Inability tolerate oral medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Advanced Cancer , Various , NOS</keyword>
</DOC>